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ABSTRACT 
The Mucopolysaccharidoses (MPS) are a class of lysosomal storage disorders, 
characterized by the primary lysosomal storage of either single or multiple species of 
glycosaminoglycan (GAG) which leads to cell, tissue, and organ dysfunction. This is manifested 
clinically by either bone/connective tissue disease, central nervous system (CNS) disease, or 
both, and often results in premature death. Mucopolysaccharidosis type III is a heterogeneous 
neuropathological disorder characterized by an accumulation of the heparan sulfate (HS). Of the 
four known types of MPS III in humans (A (OMIM: 252900), B (252920), C (252930), D 
(252940)), all have murine models except IIID. Additional to primary HS storage there is 
secondary lysosomal accumulation of multiple biological products including gangliosides. 
Mouse models are critical for advancing therapies for patients. Herein we describe the first 
mouse model of IIID. 
The MPS IIID knockout lacks exons 2-13 of the 14 exons of N-Acetylglucosamine 6-
Sulfatase (GNS) gene which encodes the enzyme (N-Acetylglucosamine 6-Sulfatase, EC 
3.1.6.14) taking part in HS degradation pathway. Affected MPS IIID mice were compared to 
affected MPS IIIB and IIIA mice, as well as to wild type (WT) mice. Affected IIID animals had 
urine retention, hepatomegaly, and rough hair coat beginning at nine months, a phenotype similar 
to other forms of MPS III. Affected animals were further characterized by histology and 
biochemistry (at four, eight and twelve months), and behavior. At four months of age there was 
no detectable liver activity of GNS and an exponential increase of GAGs was seen. Mild 
vacuolation, particularly in CNS, was seen in hematoxylin and eosin (H&E) stained tissues of 
IIID affected mice. At twelve months H&E staining showed extensive vacuolation in 
hepatocytes, renal tubular cells, CNS, as well as cerebellar Purkinje cell loss. Luxol Fast Blue 
vi 
 
 
(LFB) staining of CNS tissue showed positive staining for glycosphingolipids. The preliminary 
behavioral assessment data showed that IIID mice perform better on rotorod at least until 12 
months of age compared to IIIB mice. 
Our findings of IIID mouse are consistent with the histological and biochemical findings 
in humans. Furthermore, it has a similar phenotype and pathology to other MPS III murine 
models. 
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CHAPTER 1: LITERATURE REVIEW 
 
Lysosomal storage disorders (LSDs) are a group of inborn metabolic disorders 
comprising approximately 50 inherited disorders caused by the deficiency of particular enzymes 
or other critical elements which leads to the accumulation of one or more compounds in 
lysosomes. The mucoplysaccharidoses (MPSs) represent a class of LSDs resulting in primary 
storage of glycosaminoglycans (GAGs). At this time treatments exist for some MPSs, but there 
are no definitive cures for these disorders, which increases the need for in depth analysis of 
LSDs. 
Lysosomes 
Lysosomes, first discovered by Christian de Duve, are organelles of eukaryotic cells 
containing degrading enzymes (2). Consisting of approximately 50 hydrolytic enzymes, lysosomes 
break down and recycle different biomolecules. Initially, lysosomes were only defined as terminal 
degradative compartment of the cell but over time this definition has been expanded as the 
involvement of the lysosomes in the endocytic, autophagic, and biosynthetic pathways became 
apparent.  
Endosomal-Lysosomal Pathway 
In high order organisms, cells send or receive signals from neighboring cells in response 
to environmental cues. Communication can be in the form of different transmitters, ligands, 
nutrients etc., recognized by specific receptors on the cell membrane. The receptors along with the 
signaling molecule are internalized by the cell making a membrane bound organelle called a 
sorting endosome. As the name suggests, sorting endosomes sort the molecules to be recycled 
(mostly receptors) and molecules to be degraded (mostly ligands) into the endocytic recycling 
compartment and late endosome respectively. In the endocytic recycling compartment, the 
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molecules and/or receptors are almost 
immediately recycled to the plasma membrane or 
the trans-Golgi network (TGN). Due to a 
comparatively lower pH and the influx of 
hydrolytic enzymes from the TGN, most of the 
degradation of ligands begins in late endosomes. 
Most of the hydrolytic enzymes are targeted to 
the late endosome via a mannose 6 phosphate 
(M6P) moiety; enzymes missing this signal are 
shunted to the extracellular space via vesicular 
transport to the plasma membrane. Endosomal 
components get into the lysosome via either ‘kiss 
and run’ mechanism and/or via direct fusion. 
There are two M6P receptors (MPRs); the cation-dependent MPR (CD-MPR) and the cation-
independent MPR (CI-MPR), which are similar but not identical. Both these receptors are involved 
in lysosomal enzyme sorting at the level of the TGN with CI-MPR being the dominant receptor. 
The CI-MPR is recycled back to TGN from the endosome before the degradation process continues 
on within the lysosome. Thus, late endosomes can be distinguished from lysosomes based on the 
presence of the CI-MPRs. Figure 1 shows a schematic representation of the endocytic pathway.  
Lysosomal Storage Disorders 
The primary concept of a lysosomal storage disorder (LSD) was articulated by H.-G. Hers 
while characterizing Pompe’s disease (3). He listed four points which each disorder must have to 
be considered an LSD.  
Figure 1: Endocytic-lysosomal pathway. 
Schematic representation of endocytic-
lysosomal pathway focusing on the flow of 
compounds between Golgi network and 
endosomes. This figure has been inspired 
from (1) with modifications. 
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1) It should be a storage disease 
2) The substrate should be segregated in vacuoles related to lysosomes 
3) Normal lysosome should be able to degrade the accumulated substrate 
4) One of enzyme from the degradation pathway of the substrate should be inactive 
In the 19th century, diseases such as Gaucher, Neimann-Pick, and Tay-Sachs were first 
identified, long before de Duve’s discovery of the lysosome. In the early 20th century more diseases 
were characterized which were similar to the previously described diseases. And, in mid-20th 
century, after the discovery of lysosome and the articulation by Hers of his concept of LSDs, these 
diseases were correctly categorized as lysosomal diseases. Roughly 50 lysosomal storage diseases 
have been identified to date. Amongst these LSDs, only a few have approved therapies available. 
The LSDs differ in that they may result from different genes being affected, and within a distinct 
disease caused by a specific gene defect, there can be clinical variability ranging from severe to 
attenuated disease depending on the functional consequences of specific mutations. But, all LSDs 
are similar in that they result in an accumulation of particular substrates in lysosome.  
Classification 
Lysosomal storage disorders comprise a large group of disorders, a group which grows as 
new LSDs are identified. Classification of LSDs can be according to various approaches. The early 
description of the diseases was based on clinical signs and pathology. Such diseases were mostly 
named eponymously after the clinician(s) who identified them such as Gaucher disease, Tay-Sachs 
disease, etc. Subsequently, these diseases were defined based on histological and biochemical 
characteristics, namely the type of stored substrate, e.g. the gangliosidoses include the diseases 
which accumulate gangliosides. Similarly the MPSs include the disorders which accumulate 
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GAGs (previously known as mucopolysaccharides). This form of classification combined with the 
early classification based on the clinical signs and pathology is the classification used to date. 
An alternative, less commonly utilized, classification is based on molecular mechanism 
and the underlying type of defect that causes disease.  Six major categories or mechanisms are 
encompassed by this classification system. The first category contains the disorders caused by a 
defect in a lysosomal hydrolase’s activity. Most of the disorders come under this category such as 
Niemann-Pick disease type A (NP-A), Gaucher, Tay-Sachs, the majority of MPSs, etc. The second 
category of disorders are caused by defects in post-translational processing of the lysosomal 
enzymes, e.g. multiple sulphatase deficiency (MSD). The disorders of a third category are caused 
by trafficking defects of lysosomal enzymes, e.g. mucolipodoses type II (ML-II, a.k.a. I-cell 
disease). The majority of lysosomal enzymes which are to be targeted to the lysosome contain an 
M6P moiety. In disorders like ML this signal is missing. Thus the enzymes are secreted from the 
cell instead of trafficking to the lysosome. Not all cells in this disease are affected which implies 
that there must be an alternative pathway through which certain enzymes reach the lysosomes. The 
fourth category is a defect in lysosomal enzyme protection, e.g. galactosialidosis. In such diseases 
the lysosomal enzymes are synthesized and trafficked normally but are degraded in the lysosomes 
due to intra-lysosomal proteolysis that proceeds to degrade an enzyme because of the lack of a 
protective protein. The fifth category of disorders are caused by defects in activator proteins. 
Lysosomes contain a number of soluble non-enzymatic glycoproteins which are essential for the 
degradation of substrates. These proteins are not hydrolytic but help lysosomal hydrolases to 
function, usually by “presenting” or binding substrates, thus acting as “activator” proteins. For 
example in a form of GM2 gangliosidosis, the GM2 activator protein, which binds GM2 and 
presents it to hexosaminidase, is deficient causing the disease (4). The last category consists of the  
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Figure 2: Classification of LSDs 
Disorders are classified according to traditional convention whereas different colors indicate the 
mechanism of the defective protein. Key:      Primary lysosomal hydrolase defect,      Post-
translation processing defect of lysosomal enzyme,      Trafficking defect for lysosomal enzymes,    
Defect in lysosomal enzyme protection,      Defect in soluble non-enzymatic lysosomal proteins,       
Transmembrane (non-enzyme) protein defect. This chart has been inspired from (1) with 
modifications.   
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diseases caused by the defects in transmembrane proteins e.g. NPC-1 and MPS IIIC. Little is 
known about diseases like NPC-1 but it is suggested that either substrate shuttling, trafficking 
and/or fusion of the vesicles might be involved. This mechanistic form of classification, even 
though not frequently used, can aid in the conceptual development of therapies for LSDs. For 
example enzyme replacement therapies (ERTs) are proposed for MPS disorders but ERT is not 
predicted to be beneficial for MPS type IIIC which is caused by a defect in transmembrane 
protein. Both approaches to lysosomal storage disorder classification, a substrate approach, and a 
mechanistic approach can be seen in Figure 2. 
Epidemiology 
All lysosomal storage disorders follow Mendelian inheritance, all being autosomal 
recessive disorders with an exception of Fabry and MPS type II which are X-linked disorders. A 
study in Australia looking at the prevalence of LSDs from 1980 to 1996 estimated that, even 
though the prevalence of each LSD is low, they have aggregate prevalence of 1 per 7700 live births 
(5). Certain ethnic groups have high prevalence of specific LSDs for example the carrier frequency 
of Tay-Sachs disease among Ashkenazi Jewish populations was 1;25 in the Australian high school 
population and 1:33 in the Brazilian high school population (6, 7). Similarly there are certain 
regions and/or countries where inter-family and/or inter-caste marriages are a common practice. If 
studied, those regions will most likely have a higher incidence of lysosomal storage disorders.  
Mucopolysaccharidoses 
The MPSs are a class of lysosomal storage disorders characterized by the accumulation of one or 
more specific types of GAG. As mentioned previously the MPS disorders are autosomal 
recessive disorders with the exception of MPS II which is an X-linked syndrome. The MPSs are 
life threatening and progressive disorders, the severe forms of which may lead to death at an 
early age. There are a total of seven major MPS types, caused by the deficiency of eleven 
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different lysosomal enzymes. As multiple enzyme deficiencies may lead to the accumulation of a 
single species of GAG, some of the major types of MPSs have further subtypes for example 
MPS IIIA-IIIE. 
Classification 
The MPSs are classified on the basis of clinical disease and by the type of GAG 
accumulated. In human forms of MPS disorders eleven lysosomal enzymes consisting of five 
sulfatases, five glycosidases and one transferase take part in the catabolic pathways of five main 
classes of GAGs (8). Dermatan sulfate (DS), keratan sulfate (KS), heparan sulfate (HS), 
chondroitin sulfate (CS) and hyaluronan (HA) are stored singly or in combination, depending on 
the specific deficient activity of one of the mentioned eleven lysosomal enzymes. Table 1 lists all 
the major types and subtypes of MPS along with the corresponding accumulated GAG and the 
responsible enzyme deficiency.  
Glycosaminoglycans 
Glycosaminoglycans are complex carbohydrate conjugates (reviewed Jackson (9)), 
consisting of large linear repeating heteropolysaccharide units. These repeating units are 
disaccharides of an amino sugar (D-glucosamine or galactosamine) and a uronic acid residue (D-
glucoronic acid or iduronic acid). There are six major GAGs known as HS, heparin, DS, KS, CS, 
and HA. The amino sugar of the polysaccharide chain can be sulfated on either carbon 4 or 6, or 
the non-acetylated nitrogen, while the overall backbone can be sulfated at multiple positions. 
Amongst six major types of GAG, only HA is non-sulfated. Glycosaminoglycans may also differ 
by the glycosidic linkage between sugar rings which can either be alpha or beta linked (α or β 
linkage) which further increases the conformational diversity of GAGs. The reducing ends of 
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most of the GAGs except heparin and 
HA are covalently attached to a core 
protein. This attachment of GAGs to 
the core protein is through a 
trisaccharide chain consisting of one 
xylose and two galactose. The linkage 
of GAG in most cases is via an O-
glycosidic linkage to serine or 
threonine. These complex macromolecules attached to the core protein are called proteoglycans 
(PG). Figure 3 shows the basic structure of proteoglycans.  
Glycosaminoglycans are produced by almost all the cells. GAGs, in the form of 
proteoglycans, can either be secreted into the extra cellular matrix or reside in the plasma 
membrane. They have several functions which includes cell adhesion, growth, structure, 
signaling, differentiation, and anticoagulation, angiogenesis, metastasis, etc. As GAGs have 
diverse cellular roles, it is not surprising that when metabolism of GAGs is disrupted several 
different diseases may result.  
Clinical Symptoms 
In the MPSs, GAG accumulation leads to cell, tissue and multiorgan dysfunction, making 
it a multisystem disorder. Depending on the type of MPS pathology of the disease in certain 
organs is more predominante. The clinical signs may include soft tissue periarticular masses, 
dysmorphic facial features, short stature, organomegaly, CNS disease, etc. The clinical 
symptoms of all of the MPS types are related to the type of GAG accumulated, and the 
syndromes sharing clinical signs share a common profile of GAG accumulation. For example all 
Figure 3: Basic structure of proteoglycans 
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the types accumulating HS manifest neurodegenerative symptoms and the types where dermatan 
sulfate (DS) is accumulated show skeletal disease. Those diseases sharing both HS and DS 
accumulation manifest both neurodegenerative skeletal disease. 
Based on the clinical systems affected, MPS disorders can be divided into three major 
categories: 1) disease primarily affecting the CNS; 2) disease primarily affecting 
skeletal/connective tissue; and 3) affecting both systems. Roughly half of the MPSs show disease 
in both systems, with the others showing disease in one major system. Mucopolysaccharidosis 
type III primarily affects the CNS, and MPS IV, VI, and IX primarily affect skeletal/connective 
tissue whereas MPS I, II, and VII manifest disease of both systems. Clinically, MPS I and II are 
quite similar, both having cognitive and somatic impairments. MPS I is an autosomal recessive 
disorder whereas MPS II is X-linked syndrome. The clinical symptoms of severe forms of MPS I 
and II include skeletal deformities, hepatosplenomegaly, coarse facial features, ear, nose, and 
throat infections, short stature, and learning difficulties. Progressive neurodegenerative, cardiac, 
and respiratory disease is also observed. Corneal clouding has been seen in MPS I, VI, and VII 
patients but not in MPS II. MPS III also known as Sanfilippo syndrome is characterized by CNS 
degeneration and mild somatic impairment. Clinical symptoms of severe form of MPS III 
include hepatosplenomegaly, delayed development, aggression, cortical atrophy, dementia, 
hyperactivity, hearing loss, etc. which leads to a semi-vegetative state and an early death. 
Patients with MPS IV and VI syndrome have predominantly skeletal dysplasia. Clinical signs 
include skeletal deformities, short stature, respiratory disease, cardiac impairments, hearing 
impairment, mild corneal clouding, decreased mobility, cervical spine instability, etc. MPS VII 
or Sly syndrome resemble MPS I and II in their clinical manifestations. Only a few cases of MPS 
IX have been described. Within most of MPS types a spectrum of clinical signs is observed 
10 
 
 
Table 1: Major types of Mucopolysaccharidoses 
ID Eponym OMIM 
Enzyme 
deficiency 
Gene/locus 
Accumulated 
GAG 
Primary 
disease 
manifestation 
I-H Hurler 607014 
 
α-L-Iduronidase 
 
IDUA 
Dermatan 
sulfate, 
heparan 
sulfate 
 
Bone and CNS 
I-S Scheie 607015 
I-H/S 
Hurler-
Scheie 
607016 
II Hunter 309900 
 
Iduronate 
sulfatase 
IDS 
Dermatan 
sulfate, 
heparan 
sulfate 
 
Bone and CNS 
IIIA 
Sanfilippo 
A 
252900 
Heparan N-
sulfatase 
SGSH 
Heparan 
sulfate 
CNS 
IIIB 
Sanfilippo 
B 
252920 
α-N-Acetyl-
glucosamine 
NAGLU 
IIIC 
Sanfilippo 
C 
252930 
Acetyl-CoA:α-
glucosaminide 
acetyltransferas
e 
HGSNAT 
IIID 
Sanfilippo 
D 
252940 
N-
Acetylglucosam
ine 6-sulfatase 
GNS, G6S 
IIIE 
Sanfilippo 
E 
*600722 Arylsulfatase G ARSG 
IVA Morquio A 253000 
Galactose 6-
sulfatse 
GALNS 
Keratan 
sulfate, 
chondroitin 6-
sulfate 
Bone 
IVB Morquio B 253010 β-Galactosidase GLB1 
Keratan 
sulfate 
Bone 
V No longer used (formerly Scheie syndrome) 
VI 
Maroteaux-
Lamy 
253200 Arylsulfatase B ARSB 
Dermatan 
sulfate 
Bone 
VII Sly 253220 β-glucuronidase GUSB 
Dermatan 
sulfate, 
heparan 
sulfate, 
chondroitin 4-
, 6-sulfate 
Bone and CNS 
VIII No longer used 
IX -- 601492 Hyaluronidase HYAL1 Hyaluronan 
Bone and soft 
tissue 
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ranging from attenuated to severe symptoms. Thus a single class of MPS can be further sub 
categorized on the basis of the severity of the clinical manifestations of the disease. For example 
MPS I is sub-classified based on the severity of the clinical symptoms. A severe form of MPS I, 
also known as Hurler syndrome, is named after Dr. Gertrud Hurler who first described the 
disorder in 1919 (9). In 1962 Dr. Herold Scheie diagnosed a disorder in adults which resembled 
Hurler’s syndrome but in attenuated form (initially classified as MPS V). This attenuated form of 
MPS I is now known as Scheie syndrome (10). There is also an intermediate form of MPS I, 
which is not as severe as Hurler syndrome and not as attenuated as Scheie, thus it is known as 
Hurler-Scheie syndrome. Mucopolysaccharidosis type III also has phenotypic variability but to a 
lesser degree than seen in MPS I, with MPS III patients still having substantially shortened 
lifespans and neurodegenerative disease. 
Mucopolysaccharidosis type III 
As mentioned earlier, MPS III is an MPS disorders characterized by the exclusive 
primary accumulation of HS. Mucopolysaccharidosis III is also known eponymously as 
Sanfilippo syndrome after the pediatrician Sylvester Sanfilippo who first described MPS III 
patients in the early 1960’s (11). Clinically patients of Sanfilippo syndrome are similar to other 
MPS disorders with the exception that this syndrome is primarily characterized by severe 
nervous system degeneration and mild somatic implications (reviewed in Valstar (16) and 
Kakkis (8)). Like other type of MPS disorders clinical variation is observed in MPS III as well 
but the attenuated forms of Sanfilippo syndrome are difficult to recognize and may be 
misdiagnosed. Even in patients with severe forms of MPS III there is a delay in the diagnosis due 
to mild somatic disease manifestations and the absence of coarse facial features.  
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Sanfilippo syndrome has four types in humans, type A through type D (type IIIE is only 
found in animals (12)). These four human MPS III types accumulate the same substrate (HS) in 
cells and tissues and show similar clinical symptoms but are categorized on the basis of the 
individual patient's enzyme deficiency. Due to the similar clinical signs it is impossible to 
distinguish patients with different subtypes of Sanfilippo syndrome on a clinical basis. The 
common clinical symptoms include delayed development, sleep disorders, hyperactivity, 
aggression,  hearing loss, delayed speech articulation, neurodegeneration, progressive cortical 
atrophy, and dementia,. Loss of attention span and social and adaptive skills have also been 
observed in most of the patients. Clinical onset of the disease is usually observed between the 
age of two to six, with severe neurological degeneration being observed by the age of six to ten 
in patients with severe Sanfilippo syndrome (13). Patients with MPS III have been known to 
show autistic behavior before the onset of severe neurodegeneration (14). This aspect of the 
disease may be useful to evaluate the effect of any future therapy, but currently there are no 
approved therapies. 
One thing common between all the types of MPS III is the accumulation of HS. 
Exclusive primary accumulation of HS is the defining characteristic of MPS III but HS 
accumulation in itself is not unique to MPS III, as it is also accumulated in MPS I, II, and VII 
(Table 1). Heparan sulfate proteoglycans have numerous roles with most being localized on the 
cell surface (13). The normal function of HS as part of proteoglycans aside, the mechanism of 
neurodegeneration resulting from lysosomal HS storage is not clearly or completely understood. 
Heparan Sulfate 
Heparan sulfate is composed of repeating units of uronic acid with 14 linkages to 
glucosamine. The uronic acid residue consists of D-glucuronic acid or L-iduronic acid units 
13 
 
 
which are then attached to alternating units of α-linked glucosamine. The uronic acid residues are 
sulfated and the glucosamine residues are either sulfated or acetylated on the amino group and 
sulfated on the 6-hydroxyl group. This makes heparan a compound which may vary by the 
degrees of sulfation and the ratio of glucuronic and iduronic acid residues. Such structural 
diversity is observed both among the individual disaccharide units within a HS chain, or between 
different chains overall. Heparan sulfate overall consists of three different repeated domains; 
NA-domains (N-Acetylated), S-domains (N-Sulfated), and mixed regions which consists of both 
NA and S-domains. The low acetylated regions like NA-domains are flexible segments between 
the S-domains giving structural and conformational variability to HS. This conformational 
variability is important for multi-functionality of HS. Heparan sulfate resembles heparin to a 
high degree but there are minor structural differences which cause the difference in the functions 
of HS as compared to heparin. Heparin in general resembles the S-domain of HS hence it is 
mostly composed of sulfated disaccharides. Also, the ratio of iduronic acid in heparin is higher 
compared to HS. Heparin is used pharmacologically as an anti-coagulant and has a highly 
conserved region. Whereas, due to the conformational flexibility and the structural diversity of 
HS is a part of cell-cell signaling and cell-protein interactions. Heparan sulfate is mostly found 
either in the plasma membrane or the extra cellular matrix (reviewed (15)). 
Heparan sulfate is a structurally complex polymer hence different enzymes are a part of 
the degradation pathway of HS.  A total of three glycosidases, five sulfatases and one 
acetyltransferase are known thus far to catalyze HS. Each of these enzyme deficiency is 
associated with a lysosomal storage disorder. Figure 4 shows the degradative pathway of HS 
along with the associated Sanfilippo disorders (8). Glycosidases are responsible for cleaving the 
disaccharide terminal units where α-L-iduronidase cleaves L-iduronic acid and β-glucuronidase 
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cleaves glucucronic acid as the names suggests. Both L-iduronic acid and glucuronic acid 
disaccharide units are common amongst different types of GAGs thus deficiency of α-L-
iduronidase causes accumulation of HS and DS (MPS I) whereas β-glucuronidase deficiency 
leads to accumulation of HS, DS, and chondroitin 6-sulfate (MPS VII). The third glycosidase is 
α-N-acetylglucosaminidase which cleaves N-acetylglucosamine unit of HS. The deficiency of 
this enzyme leads to MPS IIIB. There are five known sulfatases in the catabolic pathway of HS 
which includes iduronate sulfatase, glucuronate 2-sulfatase, heparan N-sulfatase, N-
acetylglucosamine 6-sulfatase, and glucosamine-3-O-sulfatase. Iduronate sulfatase removes the 
sulfate from iduronic acid, the deficiency of which leads to accumulation of both HS and DS and 
causes MPS II. Glucuronate 2-sulfatase is required for the desulfation of sulfated glucuronic 
acid. This enzyme has not yet been associated with any lysosomal storage disease in humans. 
Heparan N-sulfatase removes sulfate from the amino group of glucosamine unit, it is also known 
as sulfamidase. The deficiency of this enzyme leads to MPS IIIA. N-acetylglucosamine 6-
sulfatase desulfates the 6-sulfated N-acetyleglucosamine in both α or β linkage. The deficiency 
of this enzyme leads to MPS IIID which is one of the rarest types of MPS III syndrome in 
humans. The last known sulfatase is arylsulfatase G (ARSG) which is a glucosamine-3-O-
sulfatase which removes the 3-O-sulfate group from the glucosamine unit. The deficiency of this 
enzyme have not been observed in humans but recently an ARSG knock mouse model has been 
characterized. ARSG deficient mice showed HS accumulation and same phenotype as other MPS 
type IIIs murine models. This new form of MPS III is named MPS IIIE. The acetyltransferase; 
enzyme for IIIC; is the only enzyme in the degradation pathway of HS which is not a hydrolase. 
It does not degrade HS directly but it is crucial for the catabolism. Acetyl-CoA: α-glucosaminide 
N-acetyletransferase is the enzyme responsible to the acetylation of the amino group of   
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Figure 4: Degradation pathway of HS 
Heparan degradation pathway focused on Sanfilippo syndrome. Enzymes in purple represents 
glycosidases, orange represents sulfatases, and purple represents transferases. This pathway is 
inspired from (8) with modifications.  
N-sulfoglucosamine sulfohydrolase (SGSH) 
Sanfilippo Syndrome A (MPS IIIA) 
α-N-acetylglucosaminidase (NAGLU) 
Sanfilippo Syndrome B (MPS IIIB) 
N-acetylglucosamine-6-sulfatase (GNS) 
Sanfilippo Syndrome D (MPS IIID)    
Heparan Sulfate Degradation 
Heparan-α-glucosaminide N-acetyltransferase 
(HGSNAT) 
Sanfilippo Syndrome C (MPS IIIC) 
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glucosamine. After heparan N-sulfatase removes the sulfate group from the glucosamine amino 
group N-acetyl transferase attaches the acetyl group to the same exposed amino group. It is a 
membrane bound protein which acetylates itself on the cytoplasmic side by the transfer of acetyl 
group from acetyl-CoA and on the luminal side due to the acidic pH this acetyl group is 
transferred to the glucosamine residue. The deficiency of this enzyme is responsible for causing 
MPS IIIC. This enzyme is membrane bound thus application of already existing therapies like 
enzyme replacement therapy is not possible and it also complicates development of new 
therapies targeting MPS IIIC.  
Epidemiology of Sanfilippo syndrome 
Sanfilippo syndrome comprises a group of rare autosomal recessive diseases. The 
prevalence of MPS III varies by population studied. Meikle et. al. while looking at the 
prevalence of LSDs in Australia also looked at some LSDs individually (5). The MPSs had a 
combined prevalence of 1 per 22,500 live births. Mucopolysaccharidosis type IIIA showed to 
have a prevalence of 1 in 114,000; MPS IIIB 1 in 211,000; MPS IIIC 1 in 1,407,000; and MPS 
IIID 1 in 1,056,000 live births. This data clearly suggests that MPS IIIC and IIID are rarest of the 
MPS III types (5). In the Czech Republic from 1975 to 2008 the combined prevalence of all 
types of MPS was 3.72 compared to MPS III which was 1.91 per 100,000 live births. The 
prevalence of MPS IIIA was 0.47, MPS IIIB was 0.02, MPS IIIC was 0.42, and for MPS IIID the 
prevalence was 0.00 per 100,000 live births (16). In a study carried out in Northern Portugal 
from 1982 to 2001, the prevalence of all types of MPS was 4.8, MPS III was 0.84, MPS IIIA 
0.00, MPS IIIB was 0.72, and MPS IIIC was 0.12 in 100,000 births (17).  In the Netherlands, the 
birth prevalence of all types of MPS was 4.5 per 100,000 births from 1970 to 1996. The 
prevalence of MPS III was 1.89 where the prevalence of MPS IIIA was 1.16, MPS IIIB 0.42, 
MPS IIIC 0.21, and MPS IIID was 0.10 per 100,000 births (18). Another study looked at the 
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prevalence of MPSs in Scandinavian countries which was calculated as the number of MPS 
patients alive as of December 31, 2007. MPS III prevalence in Norway was 4, in Sweden 
prevalence was 15, and in Denmark prevalence was 5 per 0.88, 15, and 0.92 million inhabitants 
respectively (19). In Germany the incident rate of MPS III was 1.57 per 100,000 births from 
1980 to 1995 (20).  
Table 2: Prevalence of Mucopolysaccharidoses in different countries. 
ID Czech 
Republic 
Netherland Portugal Denmark Sweden Norway Australia 
 Time period 
1975-2008 1970-1996 1982-2001 No. of patients alive as of 
12/31/2007  
1980-1996 
 
Per 100,000 live births Per million inhabitants Per live births 
MPSs  3.72 4.5 4.8 33/6.03 39/4.24 32/7.06 1/22,500 
MPS IIIs 1.91 1.89 0.84 5/0.91 15/1.63 4/0.88 -- 
MPS IIIA 0.47 1.16 0.00 -- -- -- 1/114,000 
MPS IIIB 0.02 0.42 0.72 -- -- -- 1/211,000 
MPS IIIC 0.42 0.21 0.12 -- -- -- 1/1,407,000 
MPS IIID 0.00 0.10 -- -- -- -- 1/1,056,000 
 
Looking at the prevalence of types of MPSs in different countries it is clear that MPS 
IIIC and MPS IIID are the rarest amongst all the types of MPS III. Due to the lack of patients it 
becomes hard to study the pathology of the disease and the development of new therapeutic 
strategies is also impeded. Thus animal models of these disorders are critical for further study of 
the disease at a cellular and molecular level, as well as to investigate the pathology of the disease 
and the effect of different therapies.  
Animal Models of Mucopolysaccharidosis III 
The clinical symptoms and pathology of genetic disease can be evaluated in human 
patients but in depth study of the pathology and of molecular mechanism of disease is difficult to 
study directly in the patients due to practical and ethical considerations. This situation is 
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compounded in rare hereditary diseases with few patients to study. The use of animal models 
throughout the history of medical sciences has accelerated our understanding of disease and our 
development of therapies. Both small (e.g. mice) and large (e.g. dog) have both benefits and 
limitations, but both have proven to be important for investigating rare genetic disorders. These 
animal models my result for genetic engineering (i.e. a knock out model), or may result from 
naturally occurring disease causing mutations. 
The selection of an animal model for any particular metabolic disorder is dependent on 
many factors. For example to investigate the pathology of the disease the use of small animal 
models like murine models has advantages as they have a short life span, are highly inbred, have 
shorter gestation time, can generate large number of affected animals, are easily manageable, and 
cost effective. Murine models are also effective for studying the initial response to any new 
therapy, in so called proof of principle studies. Large animal models like feline and canine 
models are very useful as they exhibit similar neurological, pathological, clinical, and 
biochemical characteristics to human patients. Also, such models are crucial for studying the 
long term effects of any therapy. Not only do such models help evaluate how effective a therapy 
is in the long run but, but they allow long term evaluation of potential side effects of a therapy in 
ways that may not be achievable with murine models. For example while working on developing 
a therapy for Niemann-Pick C disease, the administration of the drug hydroxypropyl-beta-
cyclodextrin (HPβCD) attenuated the effects of the disease in murine models. The same therapy 
when carried out in a feline model showed that after few dosages of 4000mg/kg or one dosage of 
8000mg/kg in cats, there was a significant increase in auditory threshold (21). This side effect of 
using high dosage of HPβCD was not easy to notice in murine models. 
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The use of animal models to study MPS disorders has a rich and long history. Below I 
will only discuss the murine models of MPS type III.  
Murine Models of MPS III 
 
MPS IIIA 
The murine model of MPS IIIA is a naturally occurring mouse model. It was discovered 
in 1999 by a group at Albert Einstein College of Medicine working with a colony of knockout 
mice with mannoside acetylglucosaminyltransferase 3 (Mgat3) deficiency (22). A fourteen 
month male mouse was found to have behavioral changes and scruffy appearance. This mouse 
was not the only on and others were also found among both Mgat3-/- and Mgat3+/+ mice, 
indicating the mutated line was separated from the Mgat3 line. The life span of the mice was 7-
10 months and mice at end stage had enlarged bladder, less active, rough hair coat, 
hepatosplenomegaly, etc. The clinical onset of the disease was observed between six to seven 
months of age and at approximately seven months of age corneal opacity was also noted. Upon 
further investigation the mutated mice showed zebra bodies and clear cytoplasmic accumulation 
in cells on ultrastructure from different organs including brain, liver, kidney, etc. The storage 
was within the lysosomes as revealed through LAMP1 antibodies staining. Urine and brain were 
tested for GAG accumulation demonstrating accumulation of HS. In total six hydrolase enzymes 
assays were carried out which showed that only glucosamine-N-sulfamidase had reduced activity 
(~3%) whereas the rest of the enzymes had elevated activity. This mouse model was 
characterized as MPS IIIA and soon afterwards a novel point mutation was identified in the 
sulfamidase gene in affected mice which was different from the mutations found in MPS IIIA 
patients. The MPS IIIA mice carried a missense mutation (c.G91A) which led to the change in 
corresponding amino acid from aspartate to asparagine (p.D31N) (23). 
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This mouse model has been used extensively by different groups to study pathology as 
well as therapeutic strategies. The MPS IIIA murine model was investigated for behavioral 
deficits which are observed in human MPS IIIA patients. The MPS IIIA mice showed deficits in 
motor function by 3 weeks of age in an open field test. Neuromuscular strength, gait, and 
negative geotaxis responses showed impairments beginning 15 weeks of age (24). In 2004 
Hopwood’s group looked at the response to intraperitoneal and intravenous enzyme replacement 
therapy (ERT) in MPS IIIA murine models (25). There were two groups of mice, one group 
started ERT after birth (day 0) and the second group started ERT at six weeks of age. Animals 
were given the enzyme every week till 20 weeks of age. The MPS IIIA affected male mice 
showed aggression starting at 8-10 weeks, the onset of aggression was delayed in early ERT 
group till 17 weeks of age.  Animals were also tested for spatial learning abilities at 20 weeks of 
age by Morris water maze; a common test for their ability to learn and their memory. Both 
normal and early ERT MPS IIIA mice showed decrease in search time on 3, 4, and 5th day of the 
test. The untreated IIIA and delayed ERT IIIA mice showed no improvement in the search time 
in Morris water maze test. Animals with early ERT had a significant reduction in accumulated 
GAG in brain as well as other tissues. Hence, early ERT attenuated cognitive deficits, behavioral 
aggression, and GAG accumulation in most tissues including brain before maturation of blood 
brain barrier. Intracerebral injection of recombinant human sulfamidase directly in mouse CNS 
at different age points showed that early administration was successful in attenuating the effect 
of the disease but was not able to reverse the already existing signs of neurodegeneration such as 
axonal spheroids which are postulated to interfere with retrograde axonal transport. Whereas, 
injection of a high dose of recombinant human sulfamidase in cerebral spinal fluid (CSF) via 
cisterna magna reduced GAG storage in brain by up to 62% and in spinal cord by up to 71% 
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(26). Reduction in axonal spheroids was also observed which was not seen in previous 
intracerebral injection (25). Inraventricular administration of adeno-associated vector (AAV) 
containing the gene for sulfamidase (SGSH) and Sulfatase modifying factor 1 (SUMF1; activator 
of sulfatases) showed synergistic increase in sulfamidase activity which resulted in reduction of 
GAG and improvement of motor and cognitive impairments in IIIA mice (27). The MPS IIIA 
model has also been investigated for the effect of substrate reduction therapy (SDT). Substrate 
reduction therapy uses the strategy of reducing the synthesis of the accumulated substrate which 
results in the balance of synthesis and degradation of substrate. As a therapeutic approach, SDT 
is useful when there is at least some activity in the affected individuals, such that there is not 
enough to degrade all the substrate hence the resultion. As mentioned earlier IIIA mouse model 
has about 3% of sulfamidase activity (22). Thus this model has been used to evaluate SDT. 
Rhodamine B has been known to reduce GAG synthesis and weekly administration of rhodamine 
B for six months in MPS IIIA mice showed reduced levels of GAGs in multiple tissues as well as 
excreted urine, and improvement in spatial learning and memory (28, 29).  
The MPS IIIA mouse model has been crucial in evaluating different therapies, with ERT 
and gene therapy being the most successful therapies, with bone marrow transplant and SDT as 
comparatively less successful (24-30). This model has also been useful for determining effective 
use of therapies like 1) determining most effective site of injection for ERT via CSF, e.g. 
ventricular route was most successful while lumbar was least successful (31), 2) Combination of 
multiple therapies, e.g. hematopoietic stem cell therapy (HSCT) in combination with gene 
therapy improved the pathology as well as the behavior in MPS IIIA animal whereas  HSCT 
alone did not show effective results previously (32), 3) determining effective enzyme dose, e.g. 
continual low-dose of enzyme proved to be more effective than intermittent high-dose of enzyme 
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(33), 4) effects of targeting secondary substrate storage on the pathology of the disease, e.g. 
targeting ganglioside accumulation by N-butyledeoxynojirimycin (NB-DNJ); which reduces 
ganglioside synthesis; improves learning and fear response in IIIA mice (34).  
MPS IIIB 
In 1999 Li et al. generated an MPS IIIB mouse model by disruption of exon 6 of the 
Naglu gene resulting in α-N-acetylglucosaminidase deficiency (35).  This knock out MPS IIIB 
mouse model was studied in detail and appeared normal while young but showed urinary 
retention by the age of six months. The MPS IIIB mice survived from 8-12 months and at 
approximately 12 months the mice were euthanized due to extensive urine retention, skin ulcer 
around the genitalia, walking difficulties, and unkempt fur etc. Gross pathology of several tissues 
including the brain showed vacuolated macrophages. Tissues were examined at multiple ages 
which showed that the observed pathology became more prominent with age proving the 
progressive nature of the disease. Also, in an open field test older MPS IIIB mice (4.5 months 
old) showed more suppressed activity than the controls whereas the younger MPS IIIB mice (3.5 
months old) did not have any significant difference in activity compared to controls. Enzyme 
activity of α-N-acetylglucosaminidase was unmeasurable in affected mice and was half normal 
activity in heterozygous animals. The lowest α-N-acetylglucosaminidase activity was observed 
in brain. The activity of several other hydrolytic enzymes was also tested most of which had 
elevated activity. There was a considerable increase in soluble GAGs (sGAGs) in multiple 
tissues in affected mice compared to controls. In brain tissues even controls showed a 
considerable amount of sGAGs and a slight increase was seen in affected mice. The accumulated 
sGAGs were treated with HS lyase I which removed almost all the accumulated sGAGs proving 
that the accumulated sGAG was HS. Along with GAG accumulation, a secondary accumulation 
of gangliosides (GM2, GM3) was also observed. This MPS IIIB murine model had phenotypical, 
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pathological, biochemical, and behavioral similarities with human form of MPS IIIB thus this 
model has been extensive used to explore different aspects of the disease.  
Murine model of MPS IIIB has been extensively used to study the molecular and cellular 
basis of the disease as well as the pathology. In 2002, the same group which characterized the 
murine model also observed an increase in the relative density of reactive astrocytes in affected 
mice. These astrocytes showed limited response to injury unlike astrocytes in control mice (36). 
Also, inhibition of neurogenesis was seen in affected mice as early as one month of age. The 
FGFR-1 mRNA levels in MPS IIIB mice were also reduced, possibly due to the accumulation of 
HS (36). Activation of microglia was also observed (37). These changes in neuroplasticity, 
neural cell growth, and microglial activation in MPS IIIB mice may be crucial in determining the 
molecular and cellular basis of pathology in humans as well as for the development of new 
therapies to target these disease manifestations. 
The generation of an MPS IIIB murine model allowed for development of therapies 
which could be tested efficiently and economically on a small scale. Yu et al in 2000 looked at 
the short term enzyme replacement therapy in MPS IIIB mice (38). The recombinant human 
Naglu (rhNaglu), prepared from Lec1 mutant Chinese hamster ovaries, was administered 
intravenously three times with two day intervals at three months of age. As substantial amounts 
of the enzyme were only seen in liver and spleen, the dose of the enzyme was increased and mice 
were administered enzyme five times instead of three times at three months of age. Still most of 
the enzyme activity was seen in the liver and spleen with lesser amounts were seen in other 
organs. This study showed that intravenous administration of the enzyme might not be an 
effective therapy for MPS IIIB as no activity was observed in brain. Similar results were seen in 
a gene therapy study of intravenously administered a lentiviral-Naglu bearing vector (39). 
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Transgene expression was observed in some organs but not in the brain. Thus intravenous 
administration of enzyme or gene therapy may not be useful for neurodegenerative diseases like 
MPS IIIB as enzyme or vector cannot pass the blood brain barrier. In 2002 Haiyan Fu et al., 
tested two adeno-associated viral (AAV) vectors with different promoters for gene therapy (40). 
The vectors contained human Naglu cDNA and either the cytomegalovirus (CMV) or neuron-
specific enolase (NSE) promoter. These vectors were tested in cell culture before in vivo studies. 
Vectors were directly injected into different brain areas of adult MPS IIIB mice.  For in vivo 
studies, the vectors also contained the marker gene enhanced green fluorescent protein (EGFP) to 
evaluate the distribution of the vector in the brain. After the microinjection of the vector (1 µl 
AAV) directly into the brain, transduction was seen only in the surrounding neurons of the site of 
injection. Nevertheless long-term correction was observed, with a decrease in lysosomal storage 
in a larger area surrounding the site of injection. Thus, secreted Naglu was able to defuse to the 
surrounding neurons. In another study, a single injection of vector (AAV type 2 or AAV type 5) 
directly into the brain at 6 weeks of age improved pathology which extended beyond the areas of 
the injection site (41). The accumulation of secondary substrates GM2 and GM3 was also 
reversed. Direct administration of the vector into the brain removes the difficulties and problems 
associated with the blood brain barrier but the practicality of such a therapy in humans is limited 
as multiple areas would need to be injected to treat the comparatively larger human brain. In 
2004 Zheng et al., looked at the transplantation of gene-modified bone marrow in murine model 
of MPS IIIB (42). This strategy was particularly helpful in reducing the pathology of the disease 
in the brain. As IIIB is primarily a neurodegenerative disease this strategy could prove an 
effective treatment model, but due to the safety concerns of retroviral vectors, this therapy may 
present risks when applied to humans. Substrate reduction therapy has also been tested in this 
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murine model. Genistein, a soy isoflavin, and a protein tyrosine kinase inhibitor, was 
administered daily in affected and control mice. Improvement was seen in the total amount of 
GAG in liver but not in the brain, possibly due to the blood brain barrier (43). The blood brain 
barrier remains the greatest obstacle to developing effective therapies for neurodegenerative 
diseases including MPS IIIB. The murine model of IIIB has been used to assess therapeutic 
agents that cross the blood brain barrier. To target the blood brain barrier mannitol infusion has 
been used. Mannitol is an osmotic agent which is used in medicine to open the blood brain 
barrier for a short time. Using mannitol before intravenous administration of an AAV type 2 
vector with the Naglu cDNA; helped the transduction of the CNS (44). As the blood brain barrier 
is open for only a short time period, the timely administration of the vector is critical to ensure 
effective results. McCarty et al., showed that administration of intravenous AAV eight minutes 
after mannitol infusion gives a 10 fold increase in vector transduction of CNS. This strategy 
addresses the blood brain barrier, but is also complicated by the detrimental effects of the regular 
infusion of mannitol. Recently AAV type 9 has been shown to cross the blood brain barrier. A 
single intravenous injection in adult mice improved the behavior and the life span of the affected 
animals (45). Thus far AAV9 has shown the most promising results, and pretreatment by 
mannitol further improves the outcome. Another strategy tested in an effort for developing a 
therapy for MPSs is targeting the previously proved cell traffic of nucleated maternal cells in to 
the fetus during pregnancy (46). Mononuclear cells from human umbilical cord blood 
intravenously administered to a pregnant heterozygous mouse at fifth day of gestation 
transmigrated into the embryos successfully, and the enzyme activity in all the embryos was 
similar to the heterozygous parents. In conclusion, thus far different strategies have been tested 
to treat MPS IIIB but all have advantages and limitations, and to date, none have been approved.  
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MPS IIIC 
A murine model for MPS IIIC has been recently characterized by C. Martins et al. in 
2015 (47). This murine model was created through gene trap technology (Zambrowicz et al. 
2003) and produced in C57BL/N6 murine line in 2008 by Hansen et al. (48, 49). In the MPS IIIC 
murine model, a functional fusion of the β-galactosidase and neomycin resistance 
(aminoglycoside 3’-phosphotranferase) genes, was inserted after exon 7 of the Hgsnat gene the 
deficiency of which causes IIIC. The inserted sequence also contained a stop codon such that the 
exons downstream of the inserted sequence remain untranslated. Therefore the translated protein 
contains the Hgsnat amino acids encoded from exon 1 to 7 fused to β-galactosidase and 
aminoglycoside 3’-phosphotranferase. As expected the homozygous Hgsnat-Geo mice had 
reduced N-acetyltransferase activity but an elevated β-galactosidase activity. The activity of most 
of the other lysosomal enzymes was also elevated which is expected, as similar results were seen 
in the MPS IIIB and MPS IIIA murine models. The Hgsnat knockout mice conformed to 
Mendelian inheritance of an autosomal recessive disease. Affected animals were normal at birth 
and fertile as adults. No visible differences were observed between affected and normal animals 
until 11 months, after which mice showed abnormalities in gait. Affected mice didn’t differ from 
the wild type mice motor fuction assessments. Accelerating rotorod was used to test motor 
coordination and showed no significant difference between affected and normal mice. Whereas 
the affected mice did show hyperactivity and impaired learning which increased with age. 
Pathologically these mice were similar to other MPS murine models. Also, in addition to the 
storage of GAGs, secondary accumulation of gangliosides was observed, as was seen in MPS 
IIIA and IIIB mice. The MPS IIIC murine model also showed activation of microglia and 
astrocytes, also observed in MPS IIIB mice. Neuroinflammation as well as structural changes in 
mitochondria were also noted. 
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The MPS IIIC mouse model showed similarities with other MPS murine models in 
overall pathology, biochemistry, phenotype, and behavior, but it also differed from other murine 
models. Urine retention and bladder prolapse was not observed until around 15 months whereas 
this is observed at around 9 months in MPS IIIB and IIIA mice. The MPS IIIC mice survived up 
to 80 weeks of age. This longer life span had not been observed previously in MPS III mouse 
models. This model is unusual as this MPS disorder involves a membrane bound 
acetyltransferase. This model will prove important to study MPS IIIC and to address the 
considerable challenge of treating a membrane bound enzyme deficiency. 
MPS IIIE 
The MPS IIIE is an unusual MPS III type, in that it has not yet been diagnosed in 
humans. The murine model was created by Kowalewski et al. in 2012 by knocking out the 
arylsulfatase G (ARSG) gene (12). Arylsulfatase G is responsible for removing a 3-O-sulfate 
from glucosamine units. Such glucosamine units are found in relatively low abundance in HS. 
The accumulated substrate in these mice was found to be HS, and the non-reducing HS terminus 
were 3-O-sulfated N-sulfoglucosamine units, thus confirming the role of ARSG deficiency in 
murine MPS IIID. In mutant mice lysosomal storage was seen around 12 months of age in brain 
sections which is consistent with other murine MPS III subtypes. Activation of microglia and 
astrocytes was also seen in mutant mice, similar to the observations of other MPS III murine 
models. Arsg-deficient mice showed cognitive impairment which increased with age but were 
normal in other behavior tests like rotorod and grip strength etc. These mice were similar to other 
murine models of MPS III in pathology, biochemistry, and behavior. Thus this murine model 
was categorized as a new fifth subtype of Sanfilippo syndrome which was named MPS IIIE or 
Sanfilippo syndrome type E.  
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Murine model of all Sanfilippo types exist except Sanfilippo type D. In the next chapter 
we have characterized a first model of Sanfilippo syndrome type D or MPS IIID.  
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CHAPTER 2:  
CHARACTERIZATION OF A MURINE MODEL OF 
MUCOPOLYSACCHARIDOSIS TYPE IIID 
 
Introduction 
The Mucopolysaccharidoses (MPSs) are a class of lysosomal storage disorders caused by 
the deficiency of one or more enzymes which lead to an accumulation of specific profiles of 
glycosaminoglycan (GAGs) species. Mucopolysaccharidosis type III or Sanfilippo syndrome is a 
type of MPS characterized by the accumulation of heparan sulfate (HS). Clinically MPS III 
patients have severe CNS degeneration with an accompanying wide range of mild somatic signs. 
Clinical symptoms include hyperactivity, aggression, insomnia, and loss of social skills, mental 
skills, speech etc. which progresses with age (8). There are four known types of MPS III in 
humans caused by the deficiency of four different enzymes: heparan N-sulfatase (SGSH, EC 
3.10.1.1); α-N-acetylglucosaminidase (NAGLU, EC 3.2.1.50); α-glucosamine-N-
acetyletranferase (HGSNAT, EC 2.3.1.191); and N-acetyleglucoamine-6-sulfatase (GNS/G6S, 
EC 3.1.6.14). These deficiencies cause MPS IIIA to MPS IIID respectively. A fifth type of MPS 
III, MPS IIIE, only exists in a murine knockout model, deficient in arylsulfatase G (ARSG) 
activity (12). 
All types of Sanfilippo syndrome share clinical, behavioral, biochemical, and histological 
findings in common. The first cases of Sanfilippo syndrome were characterized in early 1960’s 
by Sylvester Sanfilippo (11). Variablity in phenotype has been observed in all subtypes but 
comparatively to a lesser degree than other MPS types, perhaps because milder forms are 
difficult to recognize and either remain undiagnosed or are misdiagnosed. The first 
characterization of MPS IIID was done by Kresse et al. in 1980 who studied skin fibroblasts 
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from patients with a phenotype similar to Sanfilippo syndrome (50). Accumulation of HS was 
shown, with the accumulated HS having a N-acetylglucosamine 6-sulfate on the non-reducing 
end. As the activity of the enzymes whose deficiencies cause MPS IIIA, IIIB, and IIIC were 
normal, it was postulated that the enzyme missing in those patients was α-N-acetyleglucosamine 
6-sulfatase which desulfates the N-acetylglucosamine 6 sulfate subunit with α linkage of HS but 
not N-acetylglucosamine 6 sulfate subunit in keratan sulfate which is in β linkage. With isolation 
and characterization of the GNS enzyme it was shown that GNS desulfates the N-
acetylglucosamie 6 sulfate subunit in both α and β linkage. Patients with MPS IIID only store HS 
because of an alternative pathway exists for the degradation for keratan sulfate that is not 
degraded by GNS (51). In 1988 the cDNA of GNS gene was clone from human liver and showed 
homology with steroid sulfatase. The gene was was localized to chromosome 12 by in situ 
hybridization (52-54). More than two decades after the characterization of the index case of MPS 
IIID, the genomic DNA from the patient’s fibroblast cell line revealed a homozygous nonsense 
mutation in exon 9 of 14 (c.C1063T) which led to a premature termination of the translation (55). 
More mutations were identified as new IIID patients were diagnosed (56, 57). Not unexpectedly, 
MPS IIID patients showed phenotypic variation in disease severity. 
The MPS IIID patients have similar clinical signs and symptoms, with CNS degeneration 
predominating, as is seen in the other MPS III types. This is not unexpected as all MPS III 
patients accumulate the same substrate, i.e. HS. The MPS IIID patients also have mild somatic 
symptoms which include hypertelorism, coarse facial features, ataxia, dyspraxia, hearing loss, 
heart enlargement, and developmental delay, which are symptoms, again, seen in other MPS III 
subtypes. Histological investigations have shown moderate to mild vacuolation in multiple 
organs including kidney, liver, bone, spleen, thymus, lymph nodes, pancreas, and skeletal muscle 
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(58-60).  In all MPS IIIs patients, the enzyme deficiency is present in all cells, but some organs 
and cell types are affected more than others. Th is phenomenon likely depends on the differing 
rate and degree of HS presentation to the lysosome in different cell types. 
Since the characterization of MPS IIID in 1980 multiple cases have been studied and it 
has been shown that MPS IIID is likely the rarest type of Sanfilippo syndrome (5). With the lack 
of MPS IIID patients, the use of animal models becomes crucial for studying the pathology of 
the disease as well as developing new therapeutic strategies. Thus far spontaneous emu and 
canine models of IIIB (61, 62), canine and murine models of IIIA (22, 63, 64), and a Nubian goat 
model of IIID have been characterized (65). Other than the natural models, transgenic murine 
models exist for MPS IIIB, IIIC, and IIIE (12, 22, 35). Animal models have proven significant in 
investigating the molecular and physiological mechanism of MPS III disease. 
For MPS IIID, most of the data thus far collected has come from studying the Nubian 
goat model. The pathology and biochemistry of the Nubian goat model of IIID, characterized in 
1992, resembles the human disease biochemically and histologically (65, 66). This model was 
shown to have a nonsense mutation (C  T) resulting in truncated protein and an introduction of 
AluI restriction site (67). Along with the primary storage of un-catabolized HS, secondary 
storage of glycosphingolipids (GSLs) was also observed in the brain (68). Storage of secondary 
compounds is not unique to this model and has been observed in lysosomal storage diseases in 
general (69). In the Nubian model activity of sialidase, a degradative enzyme for ganglioside, 
and GalNAcT, an enzyme for complex GSLs biosynthesis, were reduced in affected animals (68) 
possibly the cause for elevated gangliosides. Further in-vitro studies showed that HS leads to 
inhibition of both sialidase and GalNAcT. Hence it was postulated that accumulation of GSLs 
was due to the disruption by HS of a balance in the degradative and biosynthetic enzymes. Even 
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though this large animal model was used to evaluate the basic pathology of the disease and 
response to therapy (preliminary data on response to ERT), in depth investigation of disease 
manifestation and response to further therapy was not pursued, likely due to practical and 
logistical concerns.  
Murine models of MPS disorders have proven to be the most practical first line model to 
study LSDs. Murine models are well studied, they are cost effective, experiments are less time 
consuming, and animals are easy to manage, making them an ideal model organism. Therefore, 
with the advent of new technologies, transgenic murine models of MPS IIIB, IIIC, and IIIE have 
been created (12, 35, 47). As discussed in chapter one, these murine models have been 
extensively studied. These studies have explored pathogenesis, therapy response, therapy 
optimization, and biomarker investigation. Murine models for all MPS III subtypes exist except 
for MPS IIID, leading us to acquire and characterize the murine model of MPS IIID described 
below. This new model was assessed for clinical signs, biochemistry, pathology, behavioral 
deficits, and life span. We have also compared this model with already existing MPS III 
subtypes, specifically murine MPS IIIA and IIIB.     
Materials and Methods 
 
Knockout model of MPS IIID  
A knockout murine model of MPS IIID was created by Taconic Artemis laboratory. The 
murine Gns gene contains 14 exons and resides on chromosome 10. A targeting vector was 
generated using clones from C57BL/6J bacterial artificial chromosome (BAC) library. The 
positive selection cassette in the vector consisted of puromycin resistance gene flanked by Flp-
FRT recombination sites. The deletion of the puromycin resistance gene was Flp mediated. 
Taconic Artemis C57BL/6N Tac embryonic stem (ES) cell lines were quality tested and grown 
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on a mitotically inactivated feeder layer. ES cells were transfected with linearized DNA targeting 
vector. Exon 2 to 13 were replaced with the positive selection cassette removing an 
approximately 22kb region through homologous recombination. This resulted in a predicted 
transcript missing 12 of 14 exons with a frameshift in the remaining last exon resulting in a 
premature stop codon. Puromycin resistant cells were isolated and analyzed by southern blotting 
and/or PCR. Recombinant cells were expanded, frozen and used after molecular validation. Ten 
to fifteen recombinant ES cells were injected in to a blastocyst from BALB/c female mated with 
a BALB/c male. Blastocysts for ES microinjection were removed from the uterine after 3.5 days 
post coitus. Each uterine horn of pseudo pregnant females were injected with eight injected 
blastocysts. Based on the hair coat highly chimeric mice from the progeny were bred with 
C57BL/6 females. The schematic representation of the targeting vector sequence and the 
homologous recombination in ES cell line is shown is figure 5.  
Generation of experimental animals 
Animal care and all the procedures related to animals were approved by the institutional 
animal care and use committee (IACUC) and institutional biosafety committee (IBC) of Iowa 
State University. Using MPS affected males bred with C57BL/6 Jax females, the line was 
expanded and heterozygous females from the progeny were bred to either the affected male 
parent or to additional progeny heterozygous males. At most four females were kept in one cage 
and three males in one with 24 hour food and water access. Approximately 82 experimental mice 
were generated, out of which at least three animals each were used for histology and 
biochemistry from each genotypic line at four month time point. At eight month time point only 
MPS IIID and control mice were investigated. Sixteen animals each from MPS IIIB, IIID and 
wild type lines were chosen for behavioral testing. Six animals from the sixteen animals were 
harvested at twelve month time point for biochemistry and histology and the remaining 10   
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Figure 5: Generation of MPS IIID mouse: Generation of MPS IIID C57BL/6NtTac-
Gnstm3465Arte by targeted disruption of GNS gene. FRT-mediated removal of puromycin 
sequence. 
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animals from each genotypic line continued behavioral testing and are also a part of Kaplan 
Meier curve. Animals were euthanized at humane end points either by CO2 asphyxiation or 
perfusion after anesthesia. All the animals for biochemistry were euthanized by CO2 
asphyxiation and animals for histology were perfused and fixed.  
Genotyping Animals 
Animals were identified based on toe clips taken between postnatal day 9-14, with the 
same toe clips used for DNA extraction. The samples were used for PCR reaction to genotype 
MPS IIIA, MPS IIIB, and MPS IIID animals. For MPS IIID a multiplex PCR was used for MPS 
IIID loci and Flp transgene. Five set of primers were used for the multiplex PCR. Two for Flp, 
3’-GACAAGCGTTAGTAGGCACAT-5’ and 5’-GCTGCCACTCCTCAATTGGAT-3’, and 
three primers to distinguish between the wild type and MPS IIID animals which consists of a 
common primer 3’-GTACTCATTCTTGCAGAAGACCC-5’, a wild type primer 5’-
CTTCAGTGGCGTCTACAAAGC-3’ and a primer for the knocked out locus 5’-
AGTGCCACCAAGCAGAACTC-3’. The expected fragment for Flp is 488bp, for MPS IIID 
knock out is 363bp, and for the wild type is 275bp. Flp carrying animals were identified for the 
purpose of breeding only Flp negative animals in later stages to rid the colony of the Flp 
transgene. No obvious differences were found between the animals with and without Flp. The 
primers and the PCR conditions for MPS IIIB mice were kept the same as previously published 
by Ellinwood’s group in 2012 (70).  
The mouse colony was monitored every other day for clinical signs including illness etc., 
body conditions, movement, and pregnancy. Animals were euthanized when they reached 
humane end points which included rectal prolapse, vaginal prolapse, severe hunched posture, 
low body condition, extensive urine retention, difficulty in walking, and/or hyperextension. 
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Some animals of the study were euthanized due to clinical signs such as malocclusion, head tilt 
etc. which have not been associated with the disease and are common to the inbred mouse strain 
used. 
Rotorod 
Animals were tested on rotorod every month starting from two months of age. Each 
animal was trained for two consecutive days prior to its first rotorod test which was done on the 
third day. The rotorod was set at a constant speed of ten revolutions per minute and the direction 
of the revolving rod changed after each revolution. Animals were given three trials each to stay 
on the rotorod for 300 seconds. If an animal completed the target in the first trial, then other trials 
were not carried out but if not, then only the longest performance time was used in the final 
results. Mice were weighed before each rotorod test. A total of 48 animals were enrolled in 
rotorod; 16 each from MPS IIID, MPS IIIB and wild type lines. Six out of those 16 animals per 
genotypic group were harvested at 12 months for the 12 month time point biochemistry and 
histology data and the remaining animals were used for life span data. The remaining animals 
were removed from the rotorod evaluation cohort as animals reached the humane end points 
mentioned above. The wild type mice will be removed from the rotorod two months after the 
humane end points of animals of the other genotypic lines. For the statistical analysis parameters 
including weight, age, sex and genotypic group were taken in to consideration.  
Biochemistry 
A minimum of three animals at four and twelve month time point were analyzed from 
each genotypic line for biochemistry data. At eight months of age only MPS IIID animals were 
compared with the wild type animals. Kidney, liver, and brain tissues were homogenized in a 
triton-saline solution (0.2% triton and 0.9% saline), such that tissue was homogenized in a 
volume that corresponded to 3µl triton-saline solution/1mg tissue or 10µl triton-saline 
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solution/1mg for wild type and affected tissues respectively. Protein assays were carried out on 
the same day of homogenization using Thermo Scientific Pierce BCA protein assay kit. 
Quantification of GAGs was done through Alcian Blue Dye (ABD) which binds to sulfated 
GAGs. Soluble total sulfated GAGs were quantified indirectly by measuring the amount of 
ABD, read at 595nm absorbance after the dissociation of ABD-GAG complex by the addition of 
4 M guanidium hydrochloride. 50 µl of each homogenate was used for the GAG assays and 
soluble sulfated GAGs were measured per mg of the protein. Standard curve was generated by 
dilution of heparin sulfate in 0.3% BSA previously standardized with HS. To all the samples 
BSA was added to make the final concentration same as standards i.e. 0.3% BSA.  
Tissue homogenates were also used for enzyme assays which is a flourometric assay 
using 4-methylumbelliferyl (4-MU) containing substrates. Cleavage of such a substrate by the 
enzyme in the tissue homogenate releases a florescent 4-MU molecule which emits a light at a 
specific wavelength when excited. The florescent molecules were read using a flourometer. For a 
secondary enzyme assay of β-glucoronidase all homogenates were diluted 1:1000 with nanopure 
water because less diluted samples had shown activity above the range of the flourometer used. 
For the assay 25 ul of the sample with 25 ul of water and 50 ul of substrate (4-
Methylumbelliferyl-β-D-glucuronide by CalBiochem) in 0.1 M sodium acetate buffer was 
incubated for 4 hours at 37° C.  After incubation 2 ml glycine stopper (0.32M glycine, 0.2M Na 
carbonate, pH 10.5) was added to each tube and the enzyme activity was calculated from the 
fluorescence as nMoles 4-MU/ml/hr per mg protein. Standard curve was generated by dilution of 
0.2mM 4-methylumbelliferone stock. 
A subset of liver samples from MPS IIID-/-, +/- and +/+ each were sent to Dr. Patricia 
Dickson’s lab at UCLA LABioMed for detection of GNS activity. Samples were homogenized in 
38 
 
 
reaction buffer consisting of 0.2 M sodium acetate (pH 5.6), 20 mM lead acetate, and 0.01% 
Triton X-100. A two-step fluorometric measurement of GNS activity was performed as 
described previously by He et al. (71) with modifications.  Volume of 2.5 µl tissue homogenate 
was incubated with 2.5 µl of 10 mM 4-methylumbelliferyl alpha-N-acetylglucosaminide-6-
sulfate (4-MUGNS; Toronto Research Chemicals, Toronto, Canada) in reaction buffer at 37°C 
for 1-4 hours, and the reaction was then stopped by addition of 10 µl of phosphate-citrate buffer 
(0.4 M Na2HPO4 / 0.2 M citric-acid buffer, pH 4.7).  5 µl of concentrated rhNAGLU-IGFII 
conditioned medium (specific activity > 100 nmol/hr/µl; (72)) media was supplied and incubated 
for a period equal to the GNS reaction at 37°C to release 4-MU fluorophore.  Reactions were 
quenched by the addition of 200 µl of glycine carbonate buffer, pH 10.5. Fluorescence 
measurements were obtained using a microplate reader at excitation and emission wavelengths of 
360 nm and 450 nm, respectively. One activity unit of GNS was defined as 1 nmol of 4-MU 
converted substrate per hour (first step) at 37˚C. Protein concentration was determined using 
Bradford Reagent (Bio-Rad Laboratories).  
Catalytic activity of NAGLU and β-hexosaminidase (combined A and B isoforms) liver 
tissues was determined by hydrolysis of the fluorogenic substrates, 1.0 mM 4-
methylumbelliferyl-N-acetyl-α-glucosaminide, and 1.25 mM 4-methylumbelliferyl-N-acetyl-β-
glucosaminide (EMD Millipore Chemicals) in the incubation mixture, respectively.  For both 
enzymes, a unit of activity is defined as release of 1 nmol of 4-methylumelliferone (4MU) per 
hour. Protein concentration was estimated by the Bradford method, using BSA as standard. 
Histology 
Animals were perfused; after anesthesia; intracardially with approximately 30 ml saline 
and 20 to 30 ml 4% paraformaldehyde. After perfusion animals were placed in 10% neutral 
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buffered formalin at 4° C. Tissues were dehydrated in ethanol and xylene series and embedded in 
parafin blocks which were sectioned at 5µm with a microtome. Sectioned tissues were placed on 
slides, deparaffinized, stained, and analyzed. All tissues were stained with hematoxylin and eosin 
(H&E) and brain sections were additionally stained with luxol fast blue (LFB). Stained tissues 
were evaluated by an American College of Veterinary pathologist at the College of Veterinary 
Medicine, Iowa State University.   
Statistical analysis 
Biochemistry and rotorod data were analyzed using mixed procedure of SAS (version 
9.4). Multiple comparisons of least square means were performed to determine if there were any 
statistical difference at P<0.05. Rotorod data before 9 months of age (till round 7) were not 
included in the statistical analysis because no variation was observed in the performance between 
different groups as almost all animals complete the 300 seconds target.  
Results 
A total of ~82 animals were evaluated with approximately 28 MPS IIID, 22 MPS IIIB, 4 
MPS IIIA, and 28 wild type animals. Animals were genotyped by PCR and the frequency of the 
progeny followed Mendelian inheritance (Figure 6). Animals were checked frequently for 
clinical signs. The MPS IIIB mice started showing signs between the ages of 9-12 months which 
included enlarged bladder leading to rectal/vaginal prolapse at which time animals were 
euthanized due to humane consideration. The MPS IIID mice showed similar signs of bladder 
enlargement which was seen even at gross examination at 8 months of age. Rectal and vaginal 
prolapse was not seen until 12 months of age and these animals had a better body condition than 
age matched MPS IIIB animals. The MPS IIIA mice were used for the four month time point 
only hence there was no data for the 12 month time point. But previously MPS IIIA mice have 
been shown to have similar clinical signs and behavior as MPS IIIB mice (22, 35). At gross 
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examination both MPS IIIB and MPS IIID mice had an enlarged bladder with approximately 3ml 
urine collected at 12 month time point (Figure 7). Affected mice showed reduced abdominal fat 
compared to C57BL/6 aged matched mice which have been shown to get obese with age. 
Between the ages of 9 to 12 months MPS IIID mice were only distinguished from the wild type 
mice by the rough hair coat and comparatively low body condition. MPS IIID mice did not show 
signs of ataxia till 12 months of age.  
 
 
 
 
 
 
Behavioral test 
Animals performed equally well on rotorod from round 1 to round 7, corresponding to 2-
9 months of age. No significant differences were found at 9 and 10 months of age (round 8 and 9 
Figure 7: Gross findings 
A 13 month old MPS IIID mouse 
(Gns-/-) (left), displaying classic 
signs of murine Sanfilippo 
syndrome, including enlarged 
urinary bladder (arrow), 
hepatomegaly (arrow), and 
decreased abdominal fat deposits 
compared to a 12 month old wild 
type C57BL/6 mouse (right).  
 
Figure 6: Multiplex PCR 
Bands of FLPE (488 bp), Gns null (363 bp), 
and Gns wild type (274 bp) are shown. 
FLPE and Gns genotypes are noted above 
the gel. 
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respectfully) between the least square means of performance of the animals between different 
genotypic groups (figure 8). The MPS IIIB mice performed significantly worse from MPS IIID 
and normal (p=0.0002, 0.0001 respectively) at 11 months of age (round 10) whereas 
performance of MPS IIID mice was not significantly different from normal mice (p=0.8577). No 
significant differences were found between all three genotypic lines at 12 months of age (round 
11). Figure 8 shows the least square estimate of rotorod performance of animals from each 
genotype along with the number of animals (n) evaluated at each round. 
Biochemistry 
In liver samples of approximately 4 months old animals both wild type and IIID+/- 
animals showed GNS activity. Tissue samples from wild type animals showed comparatively 
higher enzyme activity than tissues from GNS+/- animals. The IIID affected animals had no 
detectable GNS activity in approximately 4 month old liver samples (table 3). Same liver 
homogenates were assayed for NAGLU and β-hexoaminidase, both of which had elevated 
enzyme activity in GNS-/- tissues.  
Table 3: GNS activity in liver along with secondary enzyme assays 
Genotype GNS  
nmol/hr/mg protein 
NAGLU 
nmol/hr/mg protein 
β-Hex  
nmol/hr/mg protein 
GNS +/+ 2.4 0.6 378.9 
GNS +/+ 3.3 0.6 375.4 
GNS +/+ 2.6 0.6 283.9 
GNS -/+ 1.3 0.9 665.1 
GNS -/+ 1.6 2.0 1516.9 
GNS -/- No detectable activity 1.7 2486.8 
GNS -/- No detectable activity 1.6 2531.1 
GNS -/- No detectable activity 1.6 1645.0 
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Quantification of accumulated soluble sulfated GAGs was done in different tissues at 
multiple time points (Figures 9 a-d). In kidney there were significantly higher levels of s-GAGs 
in MPS IIID affected animals compared to controls at 4, 8, and 12 month time point (p= 0.0028, 
<0.0001, and <0.0001 respectively). In liver levels of s-GAGs at 4 months old MPS IIID tissues 
were not significantly high whereas at 8 months and 12 months there was a significant increase 
in accumulated s-GAGs (p= 0.125, <0.001, 0.033 respectively). Tissues of MPS IIID mice were 
also compared with IIIA and IIIB mice. As expected no significant differences in s-GAGs were 
found between different MPS IIIs affected groups. Figures 9 a & b show the comparison of MPS 
IIIA, IIIB, and IIID at different time points. The activity of β-glucoronidase was high in affected 
animals at all time points (Figure 10 a & b). Changes over time are represented by different 
alphabets in the graph, same alphabets on different bars represent no significant difference 
between the two timepoints. At four and eight month time points there was no significant 
difference in activity between GNS-/- and unaffected animals in whole kidney (p= 0.266 and 
0.076 respectively). Whereas at 12 month time point activity levels were significantly high in 
affected animals compared to the controls (p= 0.0053). Enzyme activity in liver was significantly 
elevated at all time points i.e. 4, 8, and 12 months (p= 0.019, <0.0001, and 0.0004 respectively).  
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Figure 8: Rotorod data 
Round 8 to 11 corresponds to 9-12 months of age. Different rounds were not compared with each other as the number of “n” was 
significantly different at each round giving false positive results.
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Figure 9: Accumulation of s-GAGs in tissues 
Figure 9a: Kidney: Accumulated s-GAG comparison of IIID with IIIB and IIIA. Least square 
means of soluble sulfated GAGs/mg protein. Four stars represent p value less than 0.0001, three 
stars p<0.001, two stars p<0.01, and one star p<0.05. Numbers above the bars represents the 
sample size. Changes over time represented by different alphabets in the graph, same alphabets 
on different bars represent no significant difference between the two bars. 
 
Figure 9b: Liver: Accumulated s-GAG comparison of IIID with IIIB and IIIA. Least square 
means of soluble sulfated GAGs/mg protein. Four stars represent p value less than 0.0001, three 
stars p<0.001, two stars p<0.01, and one star p<0.05. Numbers above the bars represents the 
sample size. Changes over time represented by different alphabets in the graph, same alphabets 
on different bars represent no significant difference between the two bars.   
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Figure 9c: Kidney: Accumulated s-GAG comparison of IIID with wild type. Least square means 
of soluble sulfated GAGs/mg protein. Four stars represent p value less than 0.0001, three stars 
p<0.001, two stars p<0.01, and one star p<0.05. Numbers above the bars represents the sample 
size. Changes over time represented by different alphabets in the graph, same alphabets on 
different bars represent no significant difference between the two bars. 
 
Figure 9d: Liver: Accumulated s-GAG comparison of IIID with wild type. Least square means of 
soluble sulfated GAGs/mg protein. Four stars represent p value less than 0.0001, three stars 
p<0.001, two stars p<0.01, and one star p<0.05. Numbers above the bars represents the sample 
size. Changes over time represented by different alphabets in the graph, same alphabets on 
different bars represent no significant difference between the two bars. 
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Figure 10: Secondary enzyme assays 
Figure 10a: β-glucoronidase activity in whole kidney. Least square means of the enzyme activity 
in nmol/hr/mg protein. Four stars represent p value less than 0.0001, three stars p<0.001, two 
stars p<0.01, and one star p<0.05. Numbers above the bars represents the sample size. Changes 
over time represented by different alphabets in the graph, same alphabets on different bars 
represent no significant difference between the two bars. 
 
Figure 10b:  β-glucoronidase activity in liver. Least square means of the enzyme activity in 
nmol/hr/mg protein. Four stars represent p value less than 0.0001, three stars p<0.001, two stars 
p<0.01, and one star p<0.05. Numbers above the bars represents the sample size. Changes over 
time represented by different alphabets in the graph, same alphabets on different bars represent 
no significant difference between the two bars.
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Histology 
Hematoxylin and eosin stained sections of liver, kidney, spleen, eye, and multiple areas 
of the brain of 4 month old MPS IIID-/- mice showed cytoplasmic vacuolation. Mild to moderate 
paranuclear expansions of the cytoplasm of neurons was observed in cerebellar nuclei (figure 11 
part a). Similar results were seen in the neurons of medulla oblongata (figure 11 part b). In the 
cerebellum there was no evident loss of Purkinje cells whereas some of the cells were found to 
be vacuolated (figure not shown). Neuronal satellite cells were also moderately vacuolated in the 
cerebral cortex (figure 11 part c). Brain sections stained with LFB showed dark blue granular 
cytoplasmic staining in cerebellar nuclei as well as medulla oblongata (figure 12 part a & b). 
Furthermore moderate amounts of paranuclear granular dark blue cytoplasmic staining was 
observed in cerebral cortex, midbrain, thalamus, and brainstem (figures not shown). Liver 
sections had glycogen vacuolation but at high magnification hepatocytes had fine 
peri/paranuclear vacuolations (figure 11 part d). Tubular epithelial cells in kidney were also 
finely vacuolated whereas medullary tubules looked similar to the control sections (figure 11 part 
e). There were no obvious pathological changes in spleen (figure not shown). Control mice did 
not show any pathological changes other than the artifacts like occasional dark neurons, 
glycogen vacuoles, and mild clear cytoplasmic vacuolation (figure 11 part f, g, h, i, j and figure 
12 part d, e). At 13 months of age the differences between the affected and wild type animals 
were more obvious. Five sections of the brain were evaluated consisting of caudal-middle and 
rostral-middle medulla oblongata with cerebellum, rostral cerebrum, rostral thalamus, and 
olfactory bulbs. Extensive loss of Purkinje cells in the cerebellum was observed in GNS-/- 
animals with frequent stretches of no Purkinje cells and some stretches with normal Purkinje 
cells (figure 11 part k). Some of the Purkinje cells also had cytoplasm vacuolation. Neurons in 
the medulla oblongata had mild to moderate paranuclear accumulation of finely vacuolated 
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cytoplasm (figure 11 part l). Cortical, thalamic neurons, and glial cells also had mild to moderate 
paranuclear storage of vacuolated and eosinophilic cytoplasm (glial cells figure 11 part m). 
Hepatocytes in liver sections were swollen and significantly vacuolated where some clear 
vacuoles were artifacts due to lipid storage (figure 11 part n). Small aggregates of the Kupffer 
cells were often crenated and also had pale yellow material thus the vacuoles were possibly due 
to lipofuscin. In kidney occasional lipid type vacuolation was observed just like in liver. Cortical 
tubular epithelial cells had a foamy appearance and were moderate to abundantly vacuolated 
(figure 11 part o). Urinary bladder was markedly distended with urothelium equivocally 
vacuolated (figure not shown). Spinal cord contained finely granular eosinophilic material 
(figure not shown). No specific pathologic findings were identified in the remaining tissues: 
stomach, pancreas, colon, duodenum, testis, salivary gland (mixed), jejunum, cecum, heart, lung, 
sciatic nerve (small portion),  and pelvic limb. Control sections did not have any specific 
pathological findings other than the occasional artifacts similar to the ones seen in four month 
old control mice (figure 11 part p, q, r, s, t). At approximately 13 months LFB stained brain 
sections had frequent positive cytoplasmic dark spots in cerebellar nuclei and medulla oblongata 
(figure 12 part g and h). Purkinje cells had low to moderate LFB positive staining (figure 12 part 
e). Eye sections of both four month and twelve months old animals did not have any specific 
pathological changes and the affected animals looked similar to the unaffected controls (figure 
not shown).  
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Figure 11: H&E sections 
Hematoxylin & Eosin (H&E) stained tissue sections of 4 month old GNS-/- (a-e), normal (f-j), and 13 month old GNS-/- (k-o), normal 
(p-t) animals. Panels a) 400x cerebellar nuclei w/ 600x inset b) 600x medulla oblongata c) 600x cerebral cortex d) 600x liver e) 600x 
kidney f) 400x cerebellar nuclei w/ 600x inset  g) 600x medulla oblongata h) 600x cerebral cortex i) 600x liver j) 600x kidney k) 200x 
cerebellar w/ Purkinje loss with 400x inset l) 600x medulla oblongata m) 600x glia n) 200x with 600x inset liver o) 600x kidney p) 
200x cerebellar cortex with 400x inset q) 600x medulla r) 600x glia s) 200x with 600x inset liver t) 600x kidney.        
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Figure 12: LFB stained sections 
Luxol Fast Blue (LFB) stained brain sections of 4 month old GNS-/- (a-c), normal (d-f), and 13 
month old GNS-/- (g-i), normal (j-l) animals. Panels a), d), g), j) 600x cerebellar nuclei, b), e), 
h), k) 600x medulla oblongata, and c), f), i), l) 600x Purkinje cells.  
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Discussion 
Considered in the aggregate, Sanfilippo syndrome is amongst one of the most common 
types of MPS. However, as a single enzymopathy, MPS IIID is amongst the rarest of the MPS 
IIIs. There is no approved therapy for MPS IIID, and, due to the paucity of patients, development 
of new therapies by evaluation in patient populations is not feasible. Mouse models of all MPS 
III subtypes have been previously characterized except MPS IIID. We have herein characterized 
a novel murine model of MPS IIID which was produced by TaconicArtemis GmbH. This 
knockout model was produced by knocking out exons 2 to 13 of the 14 exons of the murine Gns 
gene. This murine model of MPS IIID followed the same progressive disease pattern as seen in 
other MPS III murine models. The affected mice were healthy while young and began to show 
clinical signs from the age of 9 month onward. Affected animals had an enlarged bladder, and 
rough hair coat starting from 9 months of age. Rectal, preputial, and/or vaginal prolapse was not 
observed until 12 months on age. On gross examination, MPS IIID mice showed urine retention 
and low body fat compared to wild type mice. Affected IIID mice were also compared to MPS 
IIIA and IIIB murine mice at multiple various ages. Clinical signs of MPS IIIB mice, including 
low body condition, rough hair coat, urine retention, and rectal prolapse, were seen earlier 
compared to MPS IIID, and were evident starting at 9 months of age. Thus it may be concluded 
that MPS IIID mice may have a slightly diminished rate of disease progression, as note by the 
age of onset of signs in the MPS IIID mice compared to the MPS IIIB mice. 
Rotorod data of young MPS IIID, IIIB, and wild type mice showed no significant 
differences between any of the groups. This was an expected finding, as murine MPS III 
progresses slowly over time and signs are not visible at a young age. According to previous 
studies the performance of MPS IIIB mice on a rocking rotorod started to decline at 
approximately 9 months of age (73). Our results show a decline in the MPS IIIB performance at 
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rotorod evaluation round 10, which corresponds to 11 months of age. The MPS IIID mice 
performed better than IIIB mice at 11 months of age, suggesting that MPS IIID mice start 
showing motor deficits at a comparatively later age. At 12 months of age (round 11) we see no 
significant difference between any of the affected groups, which contrasts with the round 10 
results. We consider that this may result from a skewing of the data due to lower numbers of 
animals evaluated at the time as part of round 11. As this study progresses, we anticipate robust 
differences to become evident between the different genotypic groups. At this juncture, we 
postulate based on round 10 data that MPS IIID mice tend to perform better on rocking rotorod 
than MPS IIIB mice.  
Biochemistry data showed no detectable activity of GNS in MPS IIID-/- mice whereas 
IIID+/- and IIID+/+ mice had normal GNS activity in the tested liver samples. Previously in all 
murine models an increase of other lysosomal enzymes has been consistently observed with the 
deficiency of one enzyme (12, 22, 35, 47). A secondary enzyme assay of kidney and liver 
samples of all the MPS IIID mice showed an increased activity of β-glucuronidase. Secondary 
enzyme assays of NAGLU and β-hexoaminidase on a subset of liver samples also showed 
elevated levels in affected animals. The exact reason for the increase of lysosomal enzymes is 
not known but may be due to: an increase in synthesis of the enzyme; an increase in the stability 
of the enzyme in the presence of stored substrate; an increase in the lysosomal compartment; or 
may (probably) be an interaction of some of these potentialities. In previous murine models most 
of the lysosomal enzymes were shown to have elevated activities but this pattern was not same 
for all the enzymes (22, 35), suggesting that there is not a random mechanism involved. Further 
studies are necessary to evaluate the activity level of all lysosomal enzymes in relation to the 
stored substrate in multiple tissues. 
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The gene for α-N-acetylglucosamine-6-sulfatase is responsible for removal of sulfate 
group from α-linked glucosamine residue in HS. Hence, by knocking out the gene for GNS we 
expect storage of HS. Tissues of MPS IIID animals at different ages had a significant increase in 
the amount of accumulated sulfated GAGs (s-GAGs). The pattern of s-GAGs accumulation in 
IIID mice is similar to IIIA and IIIB animals which was expected as all MPS IIIs follow a 
comparatively similar biochemical pattern both to that seen in human patients and other animal 
models. What is striking is the statistically significant difference between MPS IIIB and MPS 
IIID liver s-GAG levels at 12 months which show MPS IIID mouse livers to have a lower s-
GAG content than MPS IIIB mice. This statistically significant difference is supported by non-
significant trends seen at 12 months in kidney (MPS IIID < MPS IIIB) and at 4 months, at which 
age MPS IIID has levels lower than both MPS IIIB and MPS IIIA. The cause of this could be: a 
lower level at the HS non-reducing end of the α-N-acetylglucosamine-6-sulfate moiety in murine 
HS, relative to the moieties recognized by the enzymes deficient in MPS IIIA and MPS IIIB; a 
salvage pathway that may reduce the levels of stored HS in MPS IIID, albeit incompletely; or an 
as yet unknown mechanism or interaction. 
Gross pathology of the H&E stained MPS IIID mice at 4 months of age revealed no 
obvious specific changes in morphology in liver, kidney, spleen, and eye but multiple brain 
sections had marked differences compared to wild type animals. In the brains of IIID-affected 
mice, there was occasional fine paranuclear cytoplasmic vacuolation of neurons and infrequent 
perineuronal satellite cells within the cerebral cortex were moderately vacuolated. Positive 
cytoplasmic staining with LFB was detected in neurons of IIID-affected mice, likely 
demonstrating ganglioside accumulation. Secondary storage of glycosphingolipids like GM2, 
GM3, and GD3 has been seen in all MPS III models previously characterized (74). At 13 months 
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of age a progressive increase in the pathology of the disease was observed. Both liver and kidney 
at this age had mild to moderate vacuolation. In the cerebellum sporadic cytoplasmic 
accumulation in some Purkinje cells was observed along with a significant decrease in Purkinje 
cells which was not present at 4 months of age. Histological data at 13 months compared to 4 
months show that MPS IIID is a progressive neurodegenerative disorder, in which somatic cells 
are affected at later stages of the disease. Pathology of MPS IIID mice is not significantly 
different from IIIB and MPS IIIA mice as expected. 
Amongst other murine models of MPS IIIs, MPS IIIA and IIIB have shown severe 
phenotypes whereas IIIC and IIIE have been known to have milder phenotype. MPS IIIC mice 
start urine retention at roughly 65 weeks, have a lifespan of up to approximately 80 weeks, and 
accumulate less s-GAGs compared to MPS IIIB mice (47). Looking at the phenotype and the 
preliminary data of the rotorod performance of MPS IIID mice we expect this new model to have 
a comparatively mild phenotype as well. Murine models with milder disease progression like 
MPS IIIC still have significant morphological changes at 12 months of age and significant 
increase in GAGs thus significant histological and biochemical changes of MPS IIID mice at 13 
months of age do not contradict with the comparatively milder phenotype of the model.  
The current research of characterizing MPS IIID murine is an ongoing study with rotorod and 
lifespan data yet to be completed. The murine model of MPS IIID phenotypically, histologically, 
and biochemically matches well with other MPS III animal models. Our study suggests that this 
model is a well suited model to investigate MPS IIID disorder.  
Future Perspectives 
The murine model of MPS IIID will aid investigations into yet unanswered questions 
relavant to Sanfilippo syndrome as well as to lysosomal storage disorders in general. Murine 
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models are cost effective, easy to manage, and have a relative short lifespan which makes 
studying progressive diseases comparatively easy. As discussed previously MPS type IIID is 
amongst the rarest forms of MPS III disorders and lack of patients makes it difficult to research 
the pathology of the disease. These practical considerations play a crucial role in research, for 
example, the natural goat model of MPS IIID, is not suitable for much in depth investigation of 
the molecular and physiological manifestations of the disease or in proof of principle therapeutic 
evaluations. Such large animal models are usually reserved for pre-clinical studies only. Murine 
models are the practical animal models for preliminary research and for testing therapeutic 
approaches. Murine models of other MPS III subtype have already been extensively explored 
and characterized as discussed in chapter one. Gene therapy, enzyme replacement therapy, 
substrate deprivation therapy are some of the therapeutic strategies which are yet to be 
investigated in MPS IIID murine model. This model is also well suited for evaluation of the 
efficacy of novel therapies. 
One potential drawback of this model is the relative slower progression of disease 
compared to other MPS III models. This may make comparative evaluations of different 
approaches to therapy less easy to conduct. However, in addition to use in therapy development, 
this model may also prove useful to explore so called windows of therapeutic opportunity, i.e. 
the age within which a therapy may be successful in establishing a significant treatment effect. In 
this respect a more slowly progressive model may actually be an asset. Finally, with respect to 
the slower onset of disease, there are potential approaches to increasing or accelerating the 
severity of disease, including, among other approaches, double knockout mice involving other 
lines of knockout mice combined with MPS IIIB.  
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Different MPS disorders result in an accumulation of one or multiple GAGs but only HS 
has been seen to associate with severe CNS disease. Investigating the role of HS in brain is one 
area that needs to be explored further as targeting therapy for CNS disorders is difficult and 
expensive due to the blood brain barrier. A better understanding of the specific HS associated 
disease, could help address these effects directly, and thereby reduce the level of enzyme 
necessary to an achievable level given current delivery methods that overcome the blood brain 
barrier. A murine model is ideally suited to studying the effects of primary accumulation of HS 
on intra- and inter-cellular pathology associated with MPS III neurodegeneration. The exact 
cause of and potential pathological effect of secondary accumulation products remains an un-
answered question. In 2012 Mohammad et al., looked at GalNAc transferase (GalNAcT) and 
MPS IIIB double knock out mice (70). The GalNAcT enzyme is required for the synthesis of 
GM2 and other complex gangliosides. By knocking out the GalNAcT gene these GSLs are not 
synthesized. All gangliosides present are the simpler forms such as GM3 and GD3. The double 
knockout mice had a rapidly progressive disease relative to MPS IIIB (euthanized at 
approximately 5 months, versus approximately 11 months for the MPS IIIB mice) and performed 
worse than MPS IIIB mice on rotorod. This study showed that GM2, a secondary accumulation 
product of MPS III, may either positively modulate the neuropathology caused by HS, or the 
absence of GM2 and other elaborate gangliosides, or some associated perturbation of ganglioside 
homeostasis, may negatively modulate the neuropathology caused by HS. 
Use of the MPS IIID mouse in the context of a GalNAcT/MPS IIID double knockout 
may help generate a model with accelerated disease, which could help in the testing of therapies, 
as well as be useful to study pathogenesis mechanisms. This approach is particularly attractive as 
both the Gns and the B4galnt1 genes in mice reside near the centromeric terminus of MmA10, 
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separated by 5.8 megabases. If these knockout alleles could be produced in cis, production of 
double affected mice will be far more efficient, with production equivalent to that of a recessive 
disease. 
Other areas of investigation, addition to the question of secondary accumulation products, 
include the basic neuropathology of MPSs with regard to neurodevelopment, neuroplasticity, and 
innate immune and inflammatory responses, e.g. microglial activation and astrocytosis, among 
other things. 
In conclusion, lysosomal storage diseases are a large group of rare metabolic disorders 
and have a combined prevalence of 1 in 7700 live births (5). Understanding the molecular and 
biochemical basis of such diseases in humans has been advanced largely by studying animal 
models. Previously the animal models used were spontaneous models (often large animal models 
characterized by veterinarians). With the advancement of technology, transgenic animal models 
have been generated, supplying a need for multiple and particularly rare diseases. These highly 
inbred small models have an advantage over large models and have been extensively studied. An 
ideal strategy for determining the efficacy of any therapeutic strategy is to study the effects of the 
therapy in small and large animal model before moving forward with clinical trials in human 
patients. With the characterization of the murine model of MPS IIID and the availability of an 
already existing large animal model (Nubian goat), development of an effective therapy for 
patients with MPS IIID disorder is an achievable goal.  
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